Ranolazine toxicity precipitating seizure in the elderly
Evan Paul Tracy1, Wilfred Furtado2, James Stanton2
1Medicine, University of Louisville, Louisville, Kentucky, USA etracy5@jh.edu.
Abstract:
An 80+ year old woman with stage III chronic kidney disease presented after having an episode of sudden stiffening, shaking and confusion. This was the third such episode that the patient had in the past 4 weeks, and the patient has never had such an episo de previously. Of note, she was prescribed ranolazine for chronic angina 6 weeks prior. She initially started taking 500 mg two times per day which was subsequently increased to 1000 two times per day. Laboratory work up revealed an elevated creatinine of 2.42 compared with baseline of 1.9. Imaging studies revealed no acute findings suggestive of stroke. Electroencephalogram demonstrated seizure activity, and lacosamide 100 mg two times per day was prescribed. During her hospital stay, ranolazine was discontinued and the patient gradually returned to her mental baseline. This case demonstrates ranolazine toxicity that manifests as new-onset epilepsy which is more likely to occur in the elderly and patients with renal dysfunction.
More Related Videos
Related Concept Videos
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...


